Last reviewed · How we verify
Tomudex (RALTITREXED)
At a glance
| Generic name | RALTITREXED |
|---|---|
| Drug class | raltitrexed |
| Target | Folate receptor beta, Folate transporter 1, Proton-coupled folate transporter |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Common side effects
Key clinical trials
- Short Neoadjuvant Hemithoracic IMRT for MPM (PHASE1,PHASE2)
- Raltitrexed in HIPEC (PHASE1)
- Effects of HIPEC on Postoperative Bowel Motility and Complications
- A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer (PHASE1)
- QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT (PHASE2)
- TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma (NA)
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer (PHASE2)
- DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tomudex CI brief — competitive landscape report
- Tomudex updates RSS · CI watch RSS